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VIROLOGY

crossm
Analytical and Clinical Comparison of Three Nucleic Acid
Ampliﬁcation Tests for SARS-CoV-2 Detection
Elizabeth Smith,a Wei Zhen,a Ryhana Manji,a Deborah Schron,b Scott Duong,a,b

Gregory J. Berrya,b

a

Infectious Disease Diagnostics, Northwell Health Laboratories, Lake Success, New York, USA

b

Department of Pathology and Laboratory Medicine, The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York, USA

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was ﬁrst
identiﬁed in December 2019 and has quickly become a worldwide pandemic. In response, many diagnostic manufacturers have developed molecular assays for SARSCoV-2 under the Food and Drug Administration (FDA) Emergency Use Authorization
(EUA) pathway. This study compared three of these assays, the Hologic Panther Fusion SARS-CoV-2 assay (Fusion), the Hologic Aptima SARS-CoV-2 assay (Aptima), and
the BioFire Defense COVID-19 test (BioFire), to determine analytical and clinical performance as well as workﬂow. All three assays showed similar limits of detection
(LODs) using inactivated virus, with 100% detection, ranging from 500 to 1,000 genome equivalents/ml, whereas use of a quantiﬁed RNA transcript standard showed
the same trend but had values ranging from 62.5 to 125 copies/ml, conﬁrming variability in absolute quantiﬁcation of reference standards. The clinical correlation
found that the Fusion and BioFire assays had a positive percent agreement (PPA) of
98.7%, followed by the Aptima assay at 94.7%, compared to the consensus result. All
three assays exhibited 100% negative percent agreement (NPA). Analysis of discordant results revealed that all four samples missed by the Aptima assay had cycle
threshold (Ct) values of ⬎37 by the Fusion assay. In conclusion, while all three assays showed similar relative LODs, we showed differences in absolute LODs depending on which standard was employed. In addition, the Fusion and BioFire assays
showed better clinical performance, while the Aptima assay showed a modest decrease in overall PPA. These ﬁndings should be kept in mind when making platform
testing decisions.

ABSTRACT

KEYWORDS SARS-CoV-2, COVID-19, EUA, molecular diagnostics, TMA, PCR,
quantiﬁed virus

T

he novel coronavirus was ﬁrst detected in the United States in Washington State on
20 January 2020 (1), and by 13 March 2020, the World Health Organization (WHO)
characterized the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreak as a worldwide pandemic (2). Since then, SARS-CoV-2 has rapidly spread across
the country. At the time of this report in June 2020, the number of cases in the United
States has reached nearly 2.2 million, and the number of deaths has exceeded 100,000,
according to the Johns Hopkins University database (3). Certain regions and cities have
much higher prevalences than others, especially the New York metropolitan area that
our laboratories serve. New York City alone now accounts for approximately 10% of the
cases in the United States (3).
SARS-CoV-2 is the etiologic agent of coronavirus disease 2019 (COVID-19), for which
symptoms can vary from mild (e.g., fever, fatigue, dry cough) to severe illness (e.g.,
dyspnea, persistent pain or pressure in the chest, hypoxia, confusion), and can ultimately lead to death, particularly for those ⱖ65 years of age and those with certain
underlying medical conditions, such as heart disease, lung disease, or diabetes (4). Even
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more challenging, some are infected with the virus but do not display any signs or
symptoms of illness, which likely has contributed to the high rate of transmission
among humans (5).
Accurate and sensitive viral detection methods are key to quickly diagnose infections and mitigate transmission. Nucleic acid ampliﬁcation tests (NAATs) are highly
sensitive and speciﬁc methods for the detection of SARS-CoV-2 RNA in respiratory
specimens. The majority of the SARS-CoV-2 NAATs available today are based on
real-time reverse transcription PCR (RT-PCR) methods, including the BioFire Defense
COVID-19 test (BioFire) and the Hologic Panther Fusion SARS-CoV-2 assay (Fusion)
evaluated in the present study. Clinical comparative data have been obtained for the
Fusion assay (6–9), but to our knowledge, there have been no comparative studies of
the BioFire assay. Recently, Hologic has developed a second NAAT, the Aptima SARSCoV-2 assay (Aptima), which has been granted Food and Drug Administration (FDA)
Emergency Use Authorization (EUA); this NAAT is based on target capture and
transcription-mediated ampliﬁcation (TMA) technologies and is run on the Panther
instrument. As with the BioFire assay, comparative evaluations have yet to be performed for this new molecular assay.
An increase in testing capability is critically needed to manage the current testing
demands and to monitor and control the spread of the virus going forward. While the
FDA has worked quickly to review and authorize more molecular diagnostic platforms
to make more options available to meet demand, real-world clinical performance and
comparative data are still lacking. These data are urgently needed to better understand
the beneﬁts and limitations of each test and how best to incorporate them into local
and national testing strategies.
Here, we present an analytical and clinical evaluation of these three sample-toanswer NAATs for the qualitative detection of SARS-CoV-2 RNA in symptomatic
patients: the Fusion assay, the Aptima assay, and the BioFire single-target COVID-19
assay.
MATERIALS AND METHODS
Specimen collection and storage. Nasopharyngeal (NP) swabs were obtained from patients with
clinical signs/symptoms of COVID-19. Each collection used a sterile swab made from Dacron, rayon, or
nylon, which was placed into 3 ml of sterile universal transport medium (UTM; from various manufacturers) after collection. Samples were then transported at room temperature, stored at 2 to 8°C for up to
72 h, and tested as soon as possible after collection. For the retrospective sample set, after routine
patient testing, aliquots of samples were taken and stored at ⫺80°C until testing of the three comparator
NAATs could take place.
Study design. Samples were selected from specimens received for routine SARS-CoV-2 testing
between April and May of 2020 that were initially tested by the Fusion assay. The selection included
symptomatic patient samples that were selected at random without bias toward speciﬁc age or gender.
A total of 150 NP samples (75 negative and 75 positive) were used for this study: 101 retrospective
specimens (51 negative and 50 positive) and 49 prospective, fresh specimens (24 negative and 25
positive). Specimens were selected to represent our laboratory’s positivity rate at the time this study was
designed (50 to 60% at beginning of April 2020) and also included positive specimens spanning the
range of positivity, including those with low viral loads (characterized by high cycle threshold [Ct] values
obtained by results from initial clinical testing). Ct values obtained from the Fusion assay during
comparative testing are also shown in Fig. S1 in the supplemental material. The 101 retrospective
specimens were initially tested per routine patient care and then immediately aliquoted and frozen at
⫺80°C, remaining frozen until this study was performed. Retrospective sample aliquots were thawed and
immediately tested on the Fusion, Aptima, and BioFire systems. Testing for prospective samples was
performed within 48 h of collection. Prospective samples were run on the Fusion, Aptima, and BioFire
systems using the original UTM sample and aliquoted directly into Hologic lysis tubes and into the
BioFire sample injection vial. This work was conducted as a quality improvement activity in order to
complete assay validation for the Aptima and BioFire assays.
Hologic Panther Fusion SARS-CoV-2 assay. The Panther Fusion SARS-CoV-2 assay (Fusion) (Hologic,
Inc., San Diego, CA) was performed on the Fusion instrument according to the manufacturer’s instructions for use. This assay targets two unique regions of the open reading frame 1ab (ORF1ab) section of
the SARS-CoV-2 viral genome. A 500-l aliquot of the primary NP swab specimen is transferred into a
specimen lysis tube containing 710 l of lysis buffer and is then loaded onto the Fusion instrument. From
this tube, the instrument removes 360 l for extraction. Each specimen is processed with an internal
control (IC), which is added via the working Fusion capture reagent-S. Nucleic acid is puriﬁed using
capture oligonucleotides and a magnetic ﬁeld and eluted in 50 l, and 5 l of the eluted nucleic acid is
added to a Fusion reaction tube. The Fusion assay ampliﬁes and detects two conserved regions of the
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TABLE 1 Summary of limit of detection results
Source and type of
material

Molecular
assay

BEI Resources quantiﬁed
inactivated virus

Exact Diagnostics quantiﬁed
synthetic RNA

Fusion
Aptima
BioFirec

Positivity rate (no. of positive samples/total no.) (%)a at indicated dilution
500
250
125
62.5
31.3
1,000b
5/5 (100) 9/10 (90)
9/10 (90)
7/10 (70)
5/10 (50)
0/10 (0)
5/5 (100)
10/10 (100) 5/10 (50)
5/10 (50)
1/10 (10)
0/10 (0)
5/5 (100)
10/10 (100) 9/10 (90)
7/10 (70)
5/10 (50)
0/10 (0)

1,000 GE/ml
500 GE/ml
500 GE/ml

Fusion
Aptima
BioFiree

1,000d
5/5 (100)
5/5 (100)
5/5 (100)

62.5 copies/ml
62.5 copies/ml
125 copies/ml

500
10/10 (100)
10/10 (100)
10/10 (100)

250
10/10 (100)
10/10 (100)
10/10 (100)

125
10/10 (100)
10/10 (100)
10/10 (100)

62.5
10/10 (100)
10/10 (100)
8/10 (80)

31.3
8/10 (80)
8/10 (80)
4/5 (80)

Final LOD

aThe

limit of detection (LOD) by positivity rate for each NAAT is highlighted in bold.
for the BEI Resources virus are given in genome equivalents (GE)/ml.
cThe numbers of replicates at each dilution that gave initial equivocal results and required repeat testing were 0 (1,000 GE/ml), 1 (500 GE/ml), 1 (250 GE/ml), 5 (125
GE/ml), 2 (62.5 GE/ml), and 0 (31.3 GE/ml).
dDilutions for the Exact Diagnostics RNA are given in copies/ml.
eThe numbers of replicates at each dilution that gave initial equivocal results and required repeat testing were 0 (1,000 copies/ml, 500 copies/ml, and 250 copies/ml),
2 (125 copies/ml), 6 (62.5 copies/ml), and 4 (31.3 copies/ml).
bDilutions

ORF1ab section of the SARS-CoV-2 viral genome. Both amplicons are detected by probes using the same
ﬂuorescent reporter, with ampliﬁcation of either or both regions contributing to a single ﬂuorescent
signal and single Ct value. Reporting of a positive specimen requires only 1 of the 2 targets to be detected
(ORF1ab region 1 or ORF1ab region 2).
Hologic Aptima SARS-CoV-2 assay. The Aptima SARS-CoV-2 assay (Aptima) (Hologic, Inc., San
Diego, CA) is a NAAT that uses target capture and transcription-mediated ampliﬁcation (TMA) technologies for the isolation and ampliﬁcation of SARS-CoV-2 RNA. This assay targets two unique regions of the
ORF1ab section of the SARS-CoV-2 viral genome and is performed on the Panther instrument. All testing
was performed according to the manufacturer’s instructions and is brieﬂy described. A 500-l aliquot of
the primary NP swab specimen is transferred into a specimen lysis tube containing 710 l of lysis buffer,
and this tube is then loaded onto the Panther instrument. From the specimen lysis tube, 360 l is taken
for each reaction. Each specimen is processed with an IC, which is added via the working target capture
reagent. Nucleic acid is puriﬁed using capture oligonucleotides and a magnetic ﬁeld, and the puriﬁed
nucleic acid is used as the template for the TMA reaction. After ampliﬁcation, chemiluminescent probes
hybridize to amplicons and emit light measured by a luminometer in relative light units (RLUs). The IC
signal and SARS-CoV-2-speciﬁc signal are differentiated by kinetic proﬁles of the labeled probes (rapid
versus slow). Assay results are determined by a cutoff based on the total number of RLU and the kinetic
curve type.
BioFire COVID-19 test. The BioFire COVID-19 test (BioFire) (BioFire Defense, Salt Lake City, UT) was
performed on the BioFire FilmArray Torch 12-bay system according to the manufacturer’s instructions.
This assay targets two unique regions of the ORF1ab section and one unique region of the ORF8 section
of the SARS-CoV-2 viral genome. The test pouch (one per sample to be tested) is prepared by injecting
hydration solution into the pouch hydration port. Using a provided transfer pipette, approximately
300 l of sample is added to the sample injection vial, followed by the addition of a single-use sample
buffer tube to the sample injection vial, which is then inverted to mix. The sample mix is injected into
the pouch sample port. Within the pouch, the sample is lysed by agitation (bead beating), and all nucleic
acid is extracted and puriﬁed using magnetic bead technology. Nested multiplex PCR is performed, and
endpoint melting curve data are used to detect and generate a result for each target assay of the BioFire
COVID-19 test.
Analytical sensitivity. The limit of detection (LOD) was determined using quantiﬁed, inactivated
(gamma-irradiated) SARS-CoV-2 material from isolate USA-WA1/2020 (NR-52287; BEI Resources, Manassas, VA) and a SARS-CoV-2 synthetic RNA quantiﬁed control containing ﬁve gene targets (E, N, ORF1ab,
RdRP, and S genes of SARS-CoV-2) from Exact Diagnostics, Fort Worth, TX (SKU COV019). The BEI
Resources material was provided at a concentration of 4.1 ⫻ 109 genome equivalents (GE)/ml (2.8 ⫻ 105
50% tissue culture infective doses [TCID50]/ml before inactivation of the virus), from which the following
serial dilutions were prepared (in GE/ml): 1,000, 500, 250, 125, 62.5, and 31.3. Dilutions were prepared
using Ambion RNA storage solution (catalog no. AM7001; Thermo Fisher Scientiﬁc) to limit the potential
of degradation of the RNA and aliquoted (with replicates ranging from 5 to 10, as shown in Table 1) for
testing across the different platforms. The same process was followed for the Exact Diagnostics control,
which had a starting concentration of 200,000 copies/ml and was diluted to make the same concentrations of serial dilutions as those made for the BEI Resources material. The LOD was deﬁned as the lowest
dilution at which all replicates were positive (100% detection rate).
Workﬂow evaluation. Workﬂow was evaluated using a calibrated timer to measure the time needed
for each step being evaluated, including hands-on time (HoT), assay run time, and total turnaround time
(TAT). HoT, assay run time, and TAT were calculated using the throughput of samples per run.
Statistical methods. The consensus result was based on the majority results of the three NAATs
(Fusion, Aptima, and BioFire) and was deﬁned as follows: consensus positive equals a positive result in
ⱖ2 of 3 NAATs; consensus negative equals a negative result in ⱖ2 of 3 NAATs. The ﬁnal result of each
September 2020 Volume 58 Issue 9 e01134-20
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TABLE 2 Clinical performance comparison of three SARS-CoV-2 NAATs for 150 NP swab specimens
Consensus result
No. of positive
samples

No. of negative
samples

Kappa ()
(ⴞ95% CI)a

McNemar’s test
(P value)

PPA (%)
(ⴞ95% CI)

NPA (%)
(ⴞ95% CI)

74
1

0
74

0.987 (0.96–1.00)

1

98.7 (0.928–0.998)

100 (0.951–1)

Aptima
Positive
Negative

71
4

0
75

0.947 (0.895–0.998)

0.1336

94.7 (0.871–0.979)

100 (0.951–1)

BioFire
Positive
Negative

74
1

0
75

0.987 (0.961–1.00)

1

98.7 (0.928–0.998)

100 (0.951–1)

Molecular assay
and result
Fusionb
Positive
Negative

a⫾,

upper/lower 95% conﬁdence interval (CI).
sample gave an invalid result and was excluded from the Fusion agreement analysis.

bOne

NAAT was based on each manufacturer’s results interpretation algorithm. The positive percent agreement (PPA), negative percent agreement (NPA), positivity rate, kappa, and two-sided (upper/lower) 95%
conﬁdence interval (CI) were calculated using Microsoft Ofﬁce Excel 365 MSO software (Microsoft,
Redmond, WA). As a measure of overall agreement, Cohen’s kappa () values were calculated, with values
categorized as follows: ⬎0.90, almost perfect; 0.90 to 0.80, strong; 0.79 to 0.60, moderate; 0.59 to
0.40, weak; 0.39 to 0.21, minimal; 0.20 to 0, none (10, 11). McNemar’s chi-square test was also calculated
using R v3.6.3 (R Core Team, Vienna, Austria) (12).

RESULTS
Analytical sensitivity. Both quantiﬁed, inactivated SARS-CoV-2 virus (BEI Resources) and Exact Diagnostics SARS-CoV-2 synthetic RNA quantiﬁed control were
used to prepare serial dilution panels (1,000 to 31.3 [GE or copies]/ml, in 2-fold
dilutions) to determine the LOD of each assay. The LOD was deﬁned as the lowest
dilution in which all replicates were detected (100% positivity rate), using the
results interpretation algorithm per the instructions for use for each assay. Using
these criteria, the LOD using inactivated SARS-CoV-2 virus was 1,000 GE/ml for the
Fusion assay, 500 GE/ml for the Aptima assay, and 500 GE/ml for the BioFire test
(Table 1). In addition, the LOD as determined using the Exact Diagnostics synthetic
RNA transcript was 62.5 copies/ml for both the Fusion and Aptima assays and 125
copies/ml for the BioFire test.
Clinical performance. After testing of the 150 clinical specimens on all three
platforms, consensus results were determined for each sample (consensus positive is a
positive result in ⱖ2 of 3 NAATs; consensus negative is a negative result in ⱖ2 of 3
NAATs), and results from each NAAT were compared to the consensus result. The
Fusion and BioFire tests exhibited the highest PPA of 98.7%, while the Aptima assay had
a PPA of 94.7% (Table 2). NPAs were 100% for all three NAATs, with no false-positive
results for any platform. Cohen’s kappa values were 0.987, 0.947, and 0.987 for the
Fusion, Aptima, and BioFire tests, respectively, all of which indicate an “almost perfect”
level of agreement with the consensus result. In addition, McNemar’s chi-square test
was performed and showed no signiﬁcant difference between each assay and the
consensus result (Table 2).
Initial equivocal or invalid results occurred for three samples out of the sample set:
two samples with equivocal results for the BioFire test and one sample with an invalid
result for the Fusion assay. The initial BioFire results for the two samples were one of
three targets detected (one of the ORF1ab targets); repeat testing gave the same result
for both samples, for an overall interpretation of “detected” as described by the
manufacturer. The initial invalid result by the Fusion assay repeated as invalid, and this
sample was removed from the overall agreement analysis for the Fusion assay; since
this sample was negative by both the Aptima and BioFire tests, giving a consensus
negative result, this sample was kept in the overall agreement analyses for the Aptima
and BioFire tests.
September 2020 Volume 58 Issue 9 e01134-20
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TABLE 3 Details of discordant samples

Sample no.
GSD-3
GSD-4

Consensus
result
Positive
Positive

GSD-6
GSD-7
GSD-23
GSD-48

Positive
Positive
Positive
Positive

aDiscordant

Individual test resulta
Fusion (Ct value)
Positive (38.1)
Positive (38.1)

Aptima
Negative
Negative

Positive (40.5)
Positive (35.7)
Negative (NA)
Positive (37.3)

Negative
Positive
Positive
Negative

BioFire (gene target)
Detected (2d/2e)
Equivocal (2a) twice,
overall detected
Detected (2a/2e)
Not detected
Detected (2a/2e)
Equivocal (2a) twice,
overall detected

sample results are highlighted in bold. NA, not applicable.

There were no discordant results among the prospective, fresh sample set; all of
the discordant samples occurred among the retrospective sample set. Of the three
NAATs evaluated, the Aptima assay had the most discordant results with the
consensus (n ⫽ 4), followed by the Fusion and BioFire tests, each with one discordant result. Discordant sample results are shown in Table 3. The four discordant
samples for Aptima had Ct values of ⱖ37.3 by the Fusion assay, indicating lower
viral titers in these samples. The discordant BioFire sample had a Ct value by the
Fusion assay of 35.7. For the ﬁve Fusion/Aptima discordant samples, the BioFire test
detected only two of three targets in each sample (samples GSD-3, GSD-6, GSD-23)
or detected one of three targets in each sample twice for an overall result of
“detected” (GSD-4, GSD-48) (Table 3).
Workﬂow. Workﬂow parameters along with basic assay characteristics are presented in Table 4. Maximum sample throughput in 8-h and 24-h time periods were
considerably higher on the Fusion and Aptima platforms (Fusion, 335 samples/8 h
and 1,150 samples/24 h; Aptima, 275 samples/8 h and 1,020 samples/24 h), while
throughput for BioFire was 72 samples/8 h and 216 samples/24 h. Hands-on time
(HoT) per specimen for the both the Fusion and Aptima assays is 1 min, whereas the
BioFire HoT is 3 min per specimen. Sample preparation for the Fusion and Aptima
assays consists of aliquoting 500 l of sample into a lysis tube. Sample preparation
for BioFire consists of ﬁve steps, including pouch hydration, sample and buffer
mixing, addition of sample/buffer to the pouch, and loading onto the instrument.

TABLE 4 Basic assay characteristics and workﬂow parameters of three EUA SARS-CoV-2 NAATsa
Result for indicated assay
Characteristic
Detection platform/system

Fusion
Panther Fusion

Aptima
Panther or Panther Fusion

Sample type

NP, OPS, LRT, NS

Sample vol required
Target region of SARS- CoV-2
Analytical sensitivity per claim
Observed analytical sensitivity for inactivated virus
Observed analytical sensitivity for RNA transcript
High-throughput processing
Throughput (no. of samples per run)

500 l (250 l for LRT)
Two regions of ORF1ab
0.01 TCID50/ml
1,000 GE/ml
62.5 copies/ml
Yes
120 (with continuous
loading)
1 min
2 h/120 samples
4 h 35 min/120 samples
2 h 25 min
6 h 35 min/120 samples
335/1,150

NP, OPS, NS, nasal
wash/aspirate
500 l
Two regions of ORF1ab
0.01 TCID50/ml
500 GE/ml
62.5 copies/ml
Yes
120 (with continuous
loading)
1 min
2 h/120 samples
5 h 30 min/120 samples
3 h 30 min
7 h 30 min/120 samples
275/1,020

HoT/sample
HoT/run
Assay processing time/run
Time to ﬁrst result
Overall TAT/run
Maximum sample throughput in 8 h/24 h
aNP,

BioFire
BioFire FilmArray Torch system,
12-bay tower
NP
300 l
Two regions of ORF1ab and ORF8
0.022 TCID50/ml (330 GE/ml)
500 GE/ml
125 copies/ml
No
12
3 min
36 min/12 samples
45 min/12 samples
45 min
1 h 21 min/12 samples
72/216

nasopharyngeal swab; NS, nasal swab; OPS, oropharyngeal swab; LRT, lower respiratory tract; HoT, hands-on time; TAT, turnaround time.
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These additional steps for BioFire account for the increased HoT per specimen, as
shown in Table 4.
DISCUSSION
The present study compared the analytical sensitivities (LODs), clinical performance,
and workﬂows of three SARS-CoV-2 NAATs for 150 NP swab specimens. Our two
independent LOD analyses revealed that while all three assays had an LOD that was
within 1 dilution factor of each other within a given control material, absolute LODs
with quantiﬁed, inactivated virus (500 to 1,000 GE/ml) were severalfold higher than the
value obtained when using quantiﬁed synthetic RNA (62.5 to 125 copies/ml). This
difference in absolute LOD values reﬂects the inherent difﬁculty in comparing standards that have been prepared and quantitated differently and that have very high
stock concentrations requiring signiﬁcant dilutions for LOD panel testing (i.e., any
quantiﬁcation error and/or pipetting error of the stock will be magniﬁed in a dilution
series). Of interest, the LOD calculations for BioFire using the synthetic RNA standard
showed ampliﬁcation in only two of three gene targets, since ORF1ab is included in the
Exact Diagnostics control but ORF8 is not included. Considering this discrepancy, the
increased LOD of the Bioﬁre assay relative to the Fusion and Aptima assays when using
the quantiﬁed synthetic RNA may possibly be due to the lack of ORF8 target material.
Our clinical correlation showed that the Fusion and Bioﬁre assays had similar PPAs
(98.7%), while the Aptima assay showed a slight decrease in PPA, at 94.7%, due to four
false-negative results among samples in the frozen retrospective set. The differences
seen among all three assays and the consensus result were not statistically signiﬁcant
when analyzed using McNemar’s chi-square test. Cohen’s kappa values also showed
almost perfect agreement (range, 0.947 to 0.987) between each assay and the consensus result. NPAs were 100% for all NAATs, suggesting that each of these assays has high
speciﬁcity.
All discordant results were false negatives compared to the consensus result, with
Fusion and BioFire each demonstrating one missed positive and Aptima demonstrating
four missed positives. A closer analysis of discordant results showed that the sample
missed by the Fusion assay (GSD-23) had only two gene targets detected by BioFire
(2a/2e), and the sample missed by the BioFire assay (GSD-7) had a Ct value of 35.7 by
the Fusion assay. All four samples missed by the Aptima assay (GSD-3, -4, -6, and -48)
had Ct values ranging from 37.3 to 40.5, suggesting that the Aptima assay may be
slightly less sensitive than the Fusion and Bioﬁre assays. Of note, two of the specimens
missed by the Aptima assay (GSD-4 and GSD-48) were also each equivocal twice by the
BioFire assay and resulted as positive per the EUA instructions for use (IFU), suggesting
that these were also weak positives by the BioFire assay.
Comparisons of workﬂows between the Fusion and the Aptima assays showed
that they were quite similar, both being optimal in high-volume testing situations
(⬎1,000 tests/24 h), whereas the BioFire assay had an advantage of fast sample-toanswer time, allowing for the faster detection and diagnosis that is useful in urgent
situations.
Other comparator studies of the Fusion assay have recently been reported, including the following: a study comparing the Fusion assay to the modiﬁed CDC assay,
GenMark ePlex, and DiaSorin Simplexa (6); a study comparing Cepheid, ID NOW, and
GenMark assays using Fusion as the reference standard (7); a study comparing Fusion,
Cepheid, DiaSorin, and cobas assays and a laboratory-developed test (LDT) (8); and a
study comparing Fusion to an in-house LDT targeting the envelope gene (9). In general,
these reports show that the Fusion SARS-CoV-2 assay is comparable, if not superior, to
other molecular platforms available for SARS-CoV-2 testing. In particular, these evaluations showed that the Fusion, DiaSorin, and Cepheid assays tended to have better
analytical sensitivity and fewer false negatives in clinical testing than other assays. The
low rate of false negatives is a critical performance aspect, as missed positive results
allow for further spread of the disease and potential patient mismanagement. These
comparison studies, while not clinical trials as would be typical of new FDA-cleared in
September 2020 Volume 58 Issue 9 e01134-20
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vitro diagnostic assays, have provided a window into the relative real-world clinical
performance characteristics of these assays, which has been a signiﬁcant knowledge
gap since these SARS-CoV-2 EUA molecular assays ﬁrst became available. Among these
knowledge gaps are relative performance data for the Aptima and BioFire tests. To our
knowledge, this is the ﬁrst report comparing both the Aptima and BioFire assays to any
other NAAT for SARS-CoV-2 detection.
It is worth noting that the LOD for the Fusion SARS-CoV-2 assay determined in this
study was 1,000 GE/ml when inactivated virus was used, while the LOD determined in
a previous study by our laboratory was 83 ⫾ 36 copies/ml (6) and an additional LOD
study performed as part of this study, once again using the same synthetic quantiﬁed
RNA standard, also previously published, showed a comparable LOD of 62.5 copies/ml.
This is an important additional new set of data that exhibits the difﬁculty of comparing
absolute LOD values when using different standards, speciﬁcally inactivated virus
versus synthetic RNA standards.
This study does have limitations, being a single-site study with a limited number of
NP swab specimens (n ⫽ 150) included in the clinical evaluation. However, this specimen set was selected to be representative of our patient population (including samples
selected without bias toward speciﬁc age or gender) and positivity rate (50 to 60% in
the beginning of April 2020) and included samples with a range of viral loads (low,
moderate, high [see Fig. S1 in the supplemental material]). One additional potential
limitation is that the Fusion assay was used to select positive results, but any bias
introduced by this selection should be minimal, considering that the proportion of
positives analyzed mirrored our true positivity rate at the time of this study. Some initial
equivocal or invalid results (n ⫽ 3) by BioFire and Fusion required retesting, but only
one remained unresolved on retesting and was removed from the agreement analysis
for the Fusion assay.
In conclusion, our data show that the Fusion, Aptima, and BioFire SARS-CoV-2 NAATs
exhibit similar LODs, even when tested using two different quantiﬁed standards. In
addition, the Fusion and BioFire assays have comparable clinical performance for
detection of SARS-CoV-2 in NP swabs, with a PPA of 98.7%, while the Aptima assay
showed a slightly lower PPA, at 94.7%. All three assays demonstrated 100% NPA,
suggesting high speciﬁcity. These performance characteristics, as well as testing volume and workﬂow requirements, should be considered when making testing platform
decisions.
SUPPLEMENTAL MATERIAL
Supplemental material is available online only.
SUPPLEMENTAL FILE 1, PDF ﬁle, 0.4 MB.
ACKNOWLEDGMENTS
Gregory Berry has previously given education seminars for Hologic, Inc., and BioFire
Diagnostics and has received honorariums.

REFERENCES
1. Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H,
Spitters C, Ericson K, Wilkerson S, Tural A, Diaz G, Cohn A, Fox L, Patel
A, Gerber SI, Kim L, Tong S, Lu X, Lindstrom S, Pallansch MA, Weldon
WC, Biggs HM, Uyeki TM, Pillai SK, Washington State 2019-nCoV Case
Investigation Team. 2020. First case of 2019 novel coronavirus in the
United States. N Engl J Med 382:929 –936. https://doi.org/10.1056/
NEJMoa2001191.
2. Centers for Disease Control and Prevention. 2020. Coronavirus disease
2019 (COVID-19) situation summary. Centers for Disease Control and
Prevention, Atlanta, GA. Updated 19 April 2020. https://www.cdc.gov/
coronavirus/2019-ncov/summary.html. Accessed 13 May 2020.
3. John Hopkins University. 2020. Coronavirus COVID-19 global cases
by the Center for Systems Science and Engineering at Johns Hopkins
University. https://gisanddata.maps.arcgis.com/apps/opsdashboard/index
.html#/bda7594740fd40299423467b48e9ecf6. Accessed 18 June 2020.
September 2020 Volume 58 Issue 9 e01134-20

4. Centers for Disease Control and Prevention. 2020. Coronavirus disease
2019 (COVID-19): people who are at higher risk for severe illness. Updated 15 April 2020. Centers for Disease Control and Prevention, Atlanta,
GA. https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/
people-at-higher-risk.html. Accessed 13 May 2020.
5. WHO-Joint Mission on Coronavirus Disease. 2020. Report of the WHOChina Joint Mission on Coronavirus Disease. https://www.who.int/docs/
default-source/coronaviruse/who-china-joint-mission-on-covid-19-ﬁnal
-report.pdf. Accessed 13 May 2020.
6. Zhen W, Manji R, Smith E, Berry GJ. 2020. Comparison of four molecular in vitro diagnostic assays for the detection of SARS-CoV-2 in
nasopharyngeal specimens. J Clin Microbiol https://doi.org/10.1128/
JCM.00743-20.
7. Zhen W, Smith E, Manji R, Schron D, Berry GJ. 2020. Clinical evaluation of
jcm.asm.org 7

Smith et al.

three sample-to-answer platforms for the detection of SARS-CoV-2. J Clin
Microbiol https://doi.org/10.1128/JCM.00783-20.
8. Lieberman JA, Pepper G, Naccache SN, Huang M, Jerome KR, Greninger
AL. 2020. Comparison of commercially available and laboratory developed assays for in vitro detection of SARS-CoV-2 in clinical laboratories.
J Clin Microbiol https://doi.org/10.1128/JCM.00821-20.
9. Hogan CA, Sahoo MK, Huang C, Garamani N, Stevens B, Zehnder J,
Pinsky BA. 2020. Comparison of the Panther Fusion and a laboratorydeveloped test targeting the envelope gene for detection of SARS-

September 2020 Volume 58 Issue 9 e01134-20

Journal of Clinical Microbiology

CoV-2. J Clin Virol 127:104383. https://doi.org/10.1016/j.jcv.2020
.104383.
10. Landis JR, Koch GG. 1977. The measurement of observer agreement for
categorical data. Biometrics 33:159–174. https://doi.org/10.2307/2529310.
11. McHugh ML. 2012. Interrater reliability: the kappa statistic. Biochem Med
(Zagreb) 22:276 –282.
12. R Core Team. 2017. R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. https://
www.R-project.org/.

jcm.asm.org 8

